Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025

Everest Medicines (HKG: 1952), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, is set to announce its full-year 2024 financial results on March 26, 2025. Investors and stakeholders eagerly await the company's performance update, as the year marked significant milestones and growth for Everest Medicines.



In 2024, Everest Medicines achieved several key milestones, including the commercial launch of NEFECON® in mainland China and Macau, and the approval of VELSIPITY® in Macau. The company also made progress in its product pipeline, with EVER001 (XNW1011) showing positive results from a Phase 1b/2a clinical trial in primary membranous nephropathy. Additionally, Everest Medicines expanded its manufacturing capabilities with the completion of its new GMP facility in Hainan, China.



Everest Medicines' revenue for the full year 2024 is expected to reach RMB 700 million, reflecting the company's strong commercial performance and the successful launch of its key products. The company's operating expenses as a percentage of revenue are expected to decline by 249%, indicating significant improvement in operating efficiency. Everest Medicines' non-IFRS loss is expected to narrow by 35%, demonstrating the company's progress towards cash flow breakeven by the end of 2025.



Looking ahead to 2025, Everest Medicines plans to continue driving revenue growth through its dual-engine strategy, which combines in-house discovery with in-licensing. The company aims to maximize synergies in its core product areas and develop products with full intellectual property rights and global rights. Everest Medicines also plans to unlock partnering and value creation opportunities with its mRNA discovery pipeline and products with global rights.

Investors and stakeholders will closely monitor Everest Medicines' full-year 2024 financial results, as the company's performance is expected to reflect its strong commercial execution and progress in its product pipeline. The company's strategic initiatives and financial guidance for 2025 will also be of great interest to the investment community.